# Reactogenicity, Safety and Immunogenicity of a LAIV А/17/Hong Kong/2017/75108 H7N9 Influenza Vaccine

> **NCT03739229** · PHASE1 · UNKNOWN · sponsor: **Research Institute of Influenza, Russia** · enrollment: 40 (estimated)

## Conditions studied

- Vaccine Adverse Reaction

## Interventions

- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** H7N9 LAIV

## Key facts

- **NCT ID:** NCT03739229
- **Lead sponsor:** Research Institute of Influenza, Russia
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-03
- **Primary completion:** 2019-06-03
- **Final completion:** 2019-07-03
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2018-11-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03739229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03739229, "Reactogenicity, Safety and Immunogenicity of a LAIV А/17/Hong Kong/2017/75108 H7N9 Influenza Vaccine". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT03739229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*